One clearance.
A continuing evidence partnership.
Gesund supported clinical validation for the lumbar-spine MRI product behind Computer Vision’s Emeralgo offering. The relationship continues as products and versions evolve.
A concrete regulatory milestone.
FDA recorded a substantial-equivalence decision for ScanDiags Ortho L-Spine MR-Q on February 21, 2025. The listing retains the historical company and device names.
The company now presents itself as Computer Vision and markets Emeralgo. We use that current identity while preserving the original name in regulatory and testimonial references.
Inspect the FDA device record ↗Repeat work across
a growing AI portfolio.
Computer Vision returns to Gesund for revalidation and validation of new products as its portfolio evolves. The value extends beyond a single study: coordinated data, expert reference work and study execution, with continuity in the evidence.
The FDA record documents the device clearance; the continuing relationship is described by Gesund.
Early evidence of delivery efficiency.
In an earlier engagement, the customer reported 4× speed and 2× cost improvement relative to in-house work or traditional CROs.
That published comparison is attributed to Stefan Voser under the former ScanDiags name. It is historical customer-reported evidence, not a current benchmark or a guarantee for every engagement.